Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Marimed (MRMD) over the last 15 years, with Q3 2025 value amounting to $23000.0.

  • Marimed's Change in Account Payables fell 9624.8% to $23000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 million, marking a year-over-year decrease of 15758.41%. This contributed to the annual value of $4.2 million for FY2024, which is 7633.68% up from last year.
  • Per Marimed's latest filing, its Change in Account Payables stood at $23000.0 for Q3 2025, which was down 9624.8% from -$2.8 million recorded in Q2 2025.
  • Marimed's Change in Account Payables' 5-year high stood at $3.2 million during Q1 2022, with a 5-year trough of -$2.8 million in Q2 2025.
  • For the 5-year period, Marimed's Change in Account Payables averaged around $263421.1, with its median value being $399000.0 (2021).
  • In the last 5 years, Marimed's Change in Account Payables surged by 478668.56% in 2021 and then crashed by 27891.57% in 2022.
  • Quarter analysis of 5 years shows Marimed's Change in Account Payables stood at -$2.0 million in 2021, then surged by 32.51% to -$1.3 million in 2022, then skyrocketed by 137.7% to $507000.0 in 2023, then crashed by 106.31% to -$32000.0 in 2024, then skyrocketed by 171.88% to $23000.0 in 2025.
  • Its Change in Account Payables stands at $23000.0 for Q3 2025, versus -$2.8 million for Q2 2025 and $86000.0 for Q1 2025.